Shares of Genentech have been buoyed by news from ASCO that Avastin will likely be preferred to Erbitux for treating lung cancer. Avastin offers an extra month of average survival time compared to Erbitux. Report [1]
Links:
[1] http://www.businessweek.com/ap/financialnews/D91236A80.htm